Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2021 Financial Results and Discuss Recent Business Highlights


Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, August 5, 2021 to report financial results for the quarter ended June 30, 2021 and discuss recent business highlights.

The dial-in numbers are (866) 211-4098 for domestic callers and (647) 689-6613 for international callers. The Conference ID number is 4968588. A live webcast of the conference call will also be available on the Investors & Media page of the company's corporate website at https://ir.aldeyra.com.

After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics is a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases. Two of the company's lead product candidates, reproxalap and ADX-629, target RASP, which are pre-cytokine, systems-based mediators of inflammation. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191 (methotrexate for intravitreal injection), a drug candidate in Phase 3 testing for the prevention of proliferative vitreoretinopathy. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.


These press releases may also interest you

at 06:35
Apogee Enterprises, Inc. will report its fiscal 2024 fourth quarter and full-year results on Thursday, April 18, 2024, before the market opens. The company will also host a conference call to discuss its financial results. This conference call will...

at 06:35
Metals Acquisition Limited ARBN 671 963 198 , a private limited company incorporated under the laws of Jersey, Channel Islands ("MAC" or the "Company") announces its Annual Report for the financial year ended 31 December 2023 ("2023 Annual Report")....

at 06:31
Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual...

at 06:30
Verde AgriTech Ltd ("Verde" or the "Company") announces its financial results for the full year ended December 31, 2023 ("FY 2023") and the fourth quarter 2023 ("Q4 2023"), as audited by Ernst & Young ("EY"). The FY 2023 audited results were...

at 06:30
Hut 8 Corp. ("Hut 8" or the "Company"), a leading, vertically integrated operator of large-scale energy infrastructure and one of North America's largest Bitcoin miners, today announced its financial results for the six months ended...

at 06:30
Three clinical programs present diversified opportunities in and outside the existing anti-VEGF market and are being progressed toward Phase 3 value inflection points  New Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy actively...



News published on and distributed by: